Healthcare >> CEO Interviews >> January 12, 2004
MICHAEL J. QUINN, Chairman and Chief Executive Officer of CardioGenesis
Corporation, is an experienced senior executive with a strong marketing,
sales and operations background. He was hired by the Board in October
2000 to stem the company's losses and set it on a course that would lead
to growth, profitability and enhanced shareholder value. Mr. Quinn and
his new management team have completely reshaped the company. Under his
leadership, the domestic and international marketing and sales
organizations have been rebuilt and revitalized, operating costs have
been slashed, the downward slide in revenue has been reversed, losses
have narrowed, the market's acceptance of the company's principal
products has been increased and a plan to expand the product focus of
CardioGenesis has been implemented. From 1976 to 2000, Mr. Quinn held a
number of senior level executive management positions including Chief
Executive Officer, President and Chief Operating Officer at several
major healthcare companies including American Hospital Supply
Corporation (V. Mueller and Scientific Products Divisions), Picker
International, Cardinal Health, Bergen Brunswig and Fisher Scientific,
all large cap public corporations. For the first time in four years,
CardioGenesis will introduce new innovative technology, which will
enable the company to expand its revenue base and begin to build on its
strong angiogenic product platform. Profile
its products?
Mr. Quinn: Our company is in the cardiovascular arena. The company
actually was founded about 11 years ago
